Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference
21 nov. 2022 16h05 HE
|
Third Harmonic Bio
CAMBRIDGE, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and...
Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update
09 nov. 2022 16h15 HE
|
Third Harmonic Bio
Successfully Completed Upsized Initial Public Offering Providing Funding Through 2025 Patient Dosing Underway in Phase 1b Chronic Inducible Urticaria Clinical Trial CAMBRIDGE, Mass., Nov. 09, 2022 ...
Third Harmonic Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
19 sept. 2022 16h10 HE
|
Third Harmonic Bio
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for...
Third Harmonic Bio Announces Pricing of Upsized Initial Public Offering
14 sept. 2022 19h33 HE
|
Third Harmonic Bio
CAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for...
Third Harmonic Bio Appoints Thomas M. Soloway to its Board of Directors
09 août 2022 08h30 HE
|
Third Harmonic Bio
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment...
Julie Person Joins Third Harmonic Bio as Chief Administrative Officer
28 juin 2022 14h14 HE
|
Third Harmonic Bio
CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of...